Simpson Thacher is representing the EQT Mid Market U.S. fund, EQT Mid Market Asia III fund and Clinical Innovations in connection with entering into an agreement to sell Clinical Innovations to LABORIE Medical Technologies in a transaction valued at $525 million. The transaction is subject to customary approvals and is expected to close in early 2020.
Founded in 1993 and headquartered in Salt Lake City, Clinical Innovations is one of the world's leading medical device companies exclusively focused on labor and delivery and neonatal intensive care. Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world.
EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 41 billion in assets under management across 20 active funds. EQT funds have portfolio companies in Europe, Asia and the U.S. with total sales of more than EUR 21 billion and approximately 127,000 employees.
The Simpson Thacher team includes Robert Langdon, Michael T. Holick, Fred De Albuquerque, Sherry Shen and Jesse Feng (M&A); Chris Brown (Credit); David Rubinsky, Jeannine McSweeney and Caitlin Fitzgerald (Executive Compensation and Employee Benefits); Jason Glover, Robert Lee and Vasanth Padaki (Funds); Jonathan Goldstein (Tax); Marcela Robledo (Intellectual Property); Sara Razi, Ellen Frye and Tomi Mendel (Antitrust); and Michael Isby (Environmental).